SB 568849

Drug Profile

SB 568849

Latest Information Update: 30 Nov 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Anxiolytics; Obesity therapies
  • Mechanism of Action Melanin-concentrating hormone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Obesity

Most Recent Events

  • 30 Nov 2004 Discontinued - Preclinical for Anxiety disorders in United Kingdom (unspecified route)
  • 30 Nov 2004 Discontinued - Preclinical for Obesity in United Kingdom (unspecified route)
  • 23 Sep 2002 Preclinical trials in Anxiety disorders in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top